Relapsed Neuroblastomas Show Frequent RAS-MAPK Pathway Mutations

The majority of patients with neuroblastoma have tumors that initially respond to chemotherapy, but a large proportion will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole-genome sequencing of 23 paired diagnostic and relapse neuroblastomas showed clonal evolution from the diagnostic tumor, with a median of 29 somatic mutations unique to the relapse sample. Eighteen of the 23 relapse tumors (78%) showed mutations predicted to activate the RAS-MAPK pathway. Seven of these events were detected only in the relapse tumor, whereas the others showed clonal enrichment. In neuroblastoma cell lines, we also detected a high frequency of activating mutations in the RAS-MAPK pathway (11/18; 61%), and these lesions predicted sensitivity to MEK inhibition in vitro and in vivo. Our findings provide a rationale for genetic characterization of relapse neuroblastomas and show that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease.

Citing Articles

15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.

Elmenawi S, Fawzy M Curr Oncol Rep. 2025; .

PMID: 40064818 DOI: 10.1007/s11912-025-01650-w.

ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.

Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.

Langenberg K, van Hooff S, Koopmans B, Strijker J, Kholosy W, Ober K Eur J Cancer. 2025; 218:115275.

PMID: 39954414 PMC: 11884408. DOI: 10.1016/j.ejca.2025.115275.

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.

Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.

Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .

PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.

References

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

Seeger R, Brodeur G, Sather H, Dalton A, Siegel S, Wong K . Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111-6. DOI: 10.1056/NEJM198510313131802. View

Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G . Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996; 334(4):225-30. DOI: 10.1056/NEJM199601253340404. View

Bown N, Cotterill S, Lastowska M, ONeill S, Pearson A, Plantaz D . Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340(25):1954-61. DOI: 10.1056/NEJM199906243402504. View

Attiyeh E, London W, Mosse Y, Wang Q, Winter C, Khazi D . Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005; 353(21):2243-53. DOI: 10.1056/NEJMoa052399. View

Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V . Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2005; 78(2):279-90. PMC: 1380235. DOI: 10.1086/499925. View

Hero B, Simon T, Spitz R, Ernestus K, Gnekow A, Scheel-Walter H . Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008; 26(9):1504-10. DOI: 10.1200/JCO.2007.12.3349. View

George R, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J . Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975-8. PMC: 2587486. DOI: 10.1038/nature07397. View

Taggart D, Dubois S, Matthay K . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008; 52(4):403-18. View

10.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

11.

Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust E, Brockman W . Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol. 2009; 27(2):182-9. PMC: 2663421. DOI: 10.1038/nbt.1523. View

12.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

13.

Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D . Circos: an information aesthetic for comparative genomics. Genome Res. 2009; 19(9):1639-45. PMC: 2752132. DOI: 10.1101/gr.092759.109. View

14.

Drmanac R, Sparks A, Callow M, Halpern A, Burns N, Kermani B . Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science. 2009; 327(5961):78-81. DOI: 10.1126/science.1181498. View

15.

Carr-Wilkinson J, OToole K, Wood K, Challen C, Baker A, Board J . High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res. 2010; 16(4):1108-18. PMC: 2842933. DOI: 10.1158/1078-0432.CCR-09-1865. View

16.

Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

17.

Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G . Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010; 28(19):3122-30. DOI: 10.1200/JCO.2009.26.7955. View

18.

Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H . NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010; 142(2):218-29. PMC: 2913027. DOI: 10.1016/j.cell.2010.06.004. View

19.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

20.

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View